I-MAB/$NBP
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About I-MAB
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
Ticker
$NBP
Sector
Primary listing
Employees
32
Headquarters
Website
I-MAB Metrics
BasicAdvanced
$488M
-
-$0.49
1.46
-
Price and volume
Market cap
$488M
Beta
1.46
52-week high
$6.79
52-week low
$0.60
Average daily volume
1.7M
Financial strength
Current ratio
22.817
Quick ratio
22.648
Long term debt to equity
1.336
Total debt to equity
1.769
Profitability
EBITDA (TTM)
-38.009
Management effectiveness
Return on assets (TTM)
-10.36%
Return on equity (TTM)
-18.46%
Valuation
Price to book
1.76
Price to tangible book (TTM)
1.76
Price to free cash flow (TTM)
7.924
Free cash flow yield (TTM)
12.62%
Free cash flow per share (TTM)
0.534
Growth
Earnings per share change (TTM)
-56.40%
3-year earnings per share growth (CAGR)
-50.34%
What the Analysts think about I-MAB
Analyst ratings (Buy, Hold, Sell) for I-MAB stock.
Bulls say / Bears say
Givastomig’s Phase 1b combination trial results showed an 83% objective response rate in first-line gastric cancer patients, with rapid and durable responses supporting its best-in-class potential. (Reuters)
As of March 31, 2025, I-Mab held $168.6 million in cash and equivalents, providing enough funding through 2027 for ongoing clinical development. (Reuters)
I-Mab regained compliance with Nasdaq’s $1.00 minimum bid price requirement on June 11, 2025, avoiding delisting risk and demonstrating market backing for its ADS. (Reuters)
I-Mab reported a net loss of $5.5 million for the second quarter of 2025, compared to net income of $25.4 million a year earlier, highlighting continued unprofitability. (Reuters)
Key clinical milestones are lacking in the near term, with topline data from the givastomig Phase 1b dose expansion study expected only in Q1 2026, and updates for partner programs ragistomig and uliledlimab set for 2H 2026, resulting in a near-term data gap. (Reuters)
The company conducted a $65 million underwritten offering of 33.3 million ADS at $1.95 per share in August 2025, significantly diluting existing shareholders ahead of major clinical inflection points. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
I-MAB Financial Performance
Revenues and expenses
I-MAB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for I-MAB stock?
I-MAB (NBP) has a market cap of $488M as of November 13, 2025.
What is the P/E ratio for I-MAB stock?
The price to earnings (P/E) ratio for I-MAB (NBP) stock is 0 as of November 13, 2025.
Does I-MAB stock pay dividends?
No, I-MAB (NBP) stock does not pay dividends to its shareholders as of November 13, 2025.
When is the next I-MAB dividend payment date?
I-MAB (NBP) stock does not pay dividends to its shareholders.
What is the beta indicator for I-MAB?
I-MAB (NBP) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.